Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and several active pre-clinical programs. Advanced clinical trials with Onconova's lead compound, rigosertib, are aimed at unmet medical needs of patients with myelodysplastic syndromes (MDS). Source
No articles found.
Caladrius is a clinical-stage biopharmaceutical company committed to the developme...
Caladrius is a clinical-stage biopharmaceutical...
SI-BONE is a medical device company that has pioneered a proprietary minimally inv...
SI-BONE is a medical device company that has pi...
The objective of Phenomix Sciences, LLC (Phenomix) is to provide healthcare soluti...
The objective of Phenomix Sciences, LLC (Phenom...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company th...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a ...
Sunesis is a biopharmaceutical company focused on the development and commercializ...
Sunesis is a biopharmaceutical company focused ...
United-Guardian, Inc. ("United") is a diversified company that conducts research, ...
United-Guardian, Inc. ("United") is a diversifi...
We are a late-stage biopharmaceutical company dedicated to bringing transformative...
We are a late-stage biopharmaceutical company d...
Join the National Investor Network and get the latest information with your interests in mind.